Monday, April 28, 2014

Mergers, research, and the long run

This is a great little article about choice.  Go to the link and read it.  The punchline is given below:

 One future is for companies to intensify research in areas of need such
as oncology, exchanging assets in order to concentrate on what they do
best. The other is to succumb to cost-stripping backed by hedge funds
for whom five years is a long time. It is a moral choice.

The future of pharma lies in research, not cuts -

No comments:

Post a Comment